CASIRIVIMAB

Approval Year

Substance Class	Protein
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	J0FI6WE1QN
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

REGN-10933

Preferred Name

English

CASIRIVIMAB

Official Name

English

CASIRIVIMAB [USAN]

Common Name

English

Casirivimab [WHO-DD]

Common Name

English

CASIRIVIMAB [JAN]

Common Name

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

INN

11861

PRIMARY

SMS_ID

300000023252

PRIMARY

RXCUI

2465242

PRIMARY

DAILYMED

J0FI6WE1QN

PRIMARY

NCI_THESAURUS

C177087

PRIMARY

Showing 1 to 5 of 9 entries

Previous1 2Next

Subunit 0

Subunit 1

Subunit 2

Subunit 3

Show entries

From	To
1_22	1_96
2_22	2_96
2_147	2_203
2_223	4_214
2_264	2_324

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Glycosylation Type

MAMMALIAN

Show entries

Glycosylation Link Type	Site
N	1_300
N	2_300

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					0EO1SV3LKY

SPIKE-1 PROTEIN SARS-COV-2

TARGET -> INHIBITOR

Comments:

In blocking studies, REGN10933, REGN10987, and REGN-COV2 mediated concentration-dependent blockade of SARS-CoV-2 RBD binding to human ACE2 with IC50 values in the subnanomolar range.

Interaction Type:

IN-VITRO

Qualification:

IC50

Amount:

[<1] NANOMOLAR (average)